Investors

Tidal is officially embarking on a second round of seed funding to accelerate our mission of supplying safe and high quality psychedelic drug products for clinical and special access applications. Numerous milestones met in 2023 have shortened the timeline to production, making this an opportune time to invest in the rapidly developing psychedelic therapeutics market.

2023 was rife with overwhelmingly positive clinical trial results, significant regulatory advancements by multiple jurisdictions, and even a call to action from Canadian Parliament and Veteran’s affairs, which all suggest that markets are beginning to shift and that evidence-backed psychedelic medicine is closer than ever to becoming a powerful therapeutic pathway to address the growing global mental health crisis.

Academic research partnerships have allowed Tidal to move to the forefront of psychedelic mushroom research and product development in Canada. With a commitment to safe, effective and reproducible naturally-based therapeutics, Tidal aims to improve the efficacy, access and approachability of psilocybin-based treatments.

Investors interested in participating in this round may request a copy of the Tidal 2024 Investor Presentation below.